JRL Environmental Antibiotic Resistence

Joint Research Laboratory on ENVIRONMENTAL ANTIBIOTIC RESISTANCE

The main objective of the Joint Research Lab on ENVIRONMENTAL ANTIBIOTIC RESISTANCE is to promote and lead scientific research and knowledge transfer on the increase of antibiotic resistance and the risk it poses to environmental and human health.

In this context and within this JRL, research groups from the Basque Science and Technology Network participate: Neiker-Tecnalia, BC3 and different research groups from the UPV/EHU. All of them will contribute their experience and scientific interests to offer holistic solutions to a problem that transversally affects human health and environmental well-being.

ENVIRONMENT

The environment is the reservoir of antibiotic resistance genes and plays a crucial role in the spread of antibiotic resistance among bacteria.

ANIMAL HEALTH

The problem of antibiotic resistance needs an approach that considers animal health as well as human health.

CLINIC

According to the WHO, antibiotic resistance is one of the greatest threats to human health, economic sustainability of health care systems, food security and socio-economic development.

MULTI-RESISTANT BACTERIA

Some pathogenic bacteria show simultaneous resistance to many or even all known antibiotics: multi-resistant and pan-resistant bacteria, respectively. These are the “superbugs”.

Millones Bacterias

Mil Antibióticos

multirresistentes

OPINIONES EXPERTAS

"A medida que reunimos más pruebas, vemos con mayor claridad y preocupación la rapidez con que estamos perdiendo medicamentos antimicrobianos de importancia crítica en todo el mundo"

Dr. Tedros Adhanom Ghebreyesus

Director General de la Organización Mundial de la Salud (OMS)

"Las muertes en todo el mundo a causa de las bacterias resistentes a los antibióticos podrían aumentar más de diez veces para 2050 si no se toman medidas para evitar su propagación"

Anthony Fauci

Director del Instituto Nacional de Alergia y Enfermedades Infecciosas

"Si no somos capaces de frenar el aumento de la resistencia a los antimicrobianos, muchos de los avances de la medicina moderna basados en la efectividad de los fármacos antibacterianos como, por ejemplo: los trasplantes de órganos sólidos y progenitores hematopoyéticos; el aumento en la supervivencia de pacientes oncológicos, inmunodeprimidos y prematuros; el éxito de cirugías complejas como la cirugía protésica, la cirugía cardiaca y otras, se perderán; e infecciones graves como la neumonía, la tuberculosis o la septicemia verán aumentada su mortalidad; e infecciones ahora leves verán aumentada su gravedad"

Dr. José Luis Díaz de Tuesta

Servicio de Microbiología. Hospital Universitario Basurto

"The history of antimicrobial chemotherapy is written in the antibiotic resistance determinants found in bacteria; with every new drug developed, new resistance genes are captured, or they adapt their genomes in order to survive. It is evolution in action"